CARLOS ANDRES QUEZADA LOAIZA

CARLOS ANDRES QUEZADA LOAIZA


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
MGMARIA PIEDAD USSETTI GIL
MARIA PIEDAD USSETTI GIL
APAlicia De Pablo
Alicia De Pablo
DFDavid Iturbe Fernández
David Iturbe Fernández
RLRosalía Laporta
Rosalía Laporta
JCJosé Manuel Cifrián
José Manuel Cifrián
Background: The clinical benefits of the common off-label use of cytomegalovirus (CMV)-specific immunoglobulin (CMV-Ig) combined with antivirals in organ transplantation have not been previously assessed. The objective was to compare the risk of CMV infection and other post-transplantation outcomes between two CMV-Ig prophylaxis regimens in lung transplant recipients; Methods: Retrospective study of 124 donor CMV positive/recipient negative (D+/R–) patients receiving preventive ganciclovir/valganciclovir for 12 months, of whom 62 received adjunctive CMV-Ig as per label indication (short regimen [SR-Ig]; i.e., 7 doses over 2.5 months) and were compared to 62 who received an extended off-label regimen (ER-Ig) consisting of 17 doses over one year after transplantation. Results: The incidence of CMV infection or disease, acute rejection, chronic lung allograft dysfunction, and survival did not differ between the two CMV-Ig schedules. Although the time to the first CMV infection after transplantation was shorter in the ER-Ig than in the SR-Ig adjunctive group (log-rank: p = 0.002), the risk was independently predicted by antiviral cessation (odds ratio = 3.74; 95% confidence interval = 1.04–13.51; p = 0.030), whereas the CMV-Ig schedule had no effect. Conclusions: Extending the adjunctive CMV-Ig prophylaxis beyond the manufacturer’s recommendations up to one year does not confer additional clinical benefits regarding lung post-transplantation outcomes.

8 May 2024 in Life
Verified
Journal Article
Open access
PDF file
DIDavid Iturbe-Fernández
David Iturbe-Fernández
APAlicia De Pablo
Alicia De Pablo
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
RMRodrigo Alonso Moralejo
Rodrigo Alonso Moralejo
CLCARLOS ANDRES QUEZADA LOAIZA
CARLOS ANDRES QUEZADA LOAIZA
JCJosé Manuel Cifrián
José Manuel Cifrián
Our study aims to evaluate the effect of everolimus treatment on lung function in lung transplant (LT) patients with established chronic lung allograft dysfunction (CLAD). Methods: This retrospective study included LT patients in two reference LT units who started everolimus therapy to treat CLAD from October 2008 to October 2016. We assessed the variation in the maximum forced expiratory volume in the first second (FEV1) before and after the treatment. Results: Fifty-seven patients were included in this study. The variation in the FEV1 was −102.7 (149.6) mL/month before starting everolimus compared to −44.7 (109.6) mL/month within the first three months, +1.4 (63.5) mL/month until the sixth month, and −7.4 (46.2) mL/month until the twelfth month (p < 0.05). Glomerular filtrate remained unchanged after everolimus treatment [59.1 (17.5) mL/min per 1.73 m2 at baseline and 60.9 (19.6) mL/min per 1.73 m2, 57.7 (20.5) mL/min per 1.73 m2, and 57.3 (17.8) mL/min per 1.73 m2, at 1, 3, and 6 months, respectively] (p > 0.05). Everolimus was withdrawn in 22 (38.6%) patients. The median time to withdrawal was 14.1 (5.5–25.1) months. Conclusions: This study showed an improvement in FEV1 decline in patients with CLAD treated with everolimus. However, the drug was withdrawn in a high proportion of patients.

12 August 2026 in Life
Verified
Journal Article
Open access
PDF file
MGMiguel Jiménez Gómez
Miguel Jiménez Gómez
BMBeatriz Montull-Veiga
Beatriz Montull-Veiga
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
EREva Revilla-López
Eva Revilla-López
MAMyriam Aguilar-Pérez
Myriam Aguilar-Pérez
RMRodrigo Alonso Moralejo
Rodrigo Alonso Moralejo
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are clinically relevant pathogens in lung transplant (LT) recipients, but their impact on lung function and the benefit of ribavirin remains uncertain. We conducted a prospective multicenter observational cohort study of adult LT recipients with RSV or hMPV infection diagnosed between 2021 and 2024 at five centers, with follow-up for up to 12 months. Ribavirin was prescribed at the treating physician’s discretion. Multivariable analysis assessed the association between ribavirin and percentage change in forced expiratory volume in the first second (FEV1) at 90 days, using FEV1 three months before infection as baseline and adjusting for baseline FEV1, pre-existing chronic lung allograft dysfunction, and time since transplantation. Seventy-six patients were included; 60 (78.9%) had RSV and 16 (21.1%) hMPV. Lower respiratory tract infection occurred in 48.7%, and an acute ≥10% FEV1 decline at 14 days was observed in 29.3%. Among patients with lower respiratory tract infection, 45.9% received corticosteroids alone and 37.8% corticosteroids plus ribavirin. No statistically significant between-group differences in allograft dysfunction or mortality were observed. RSV and hMPV infections after LT were frequently associated with lower respiratory involvement and lung function decline. In this observational cohort, ribavirin use was not independently associated with 90-day FEV1 change; however, residual confounding and limited statistical power preclude conclusions regarding treatment efficacy.